<DOC>
	<DOCNO>NCT00361244</DOCNO>
	<brief_summary>The purpose study determine safety SU011248 high dose drug give safely combination chemotherapy drug irinotecan cetuximab . Laboratory study show SU011248 may block growth blood vessel tumor , may prevent tumor grow . Other study demonstrate possibility SU011248 may enhance anti-tumor activity chemotherapy drug irinotecan cetuximab .</brief_summary>
	<brief_title>SU011248 Combination With Irinotecan Cetuximab Second Line Regimen Stage IV Colorectal Cancer</brief_title>
	<detailed_description>- Participants give supply SU011248 capsule take home morning two week . After take capsule two week , one-week rest period . - Irinotecan administered day 1 8 every 21-day cycle intravenous infusion 90 minute . Cetuximab administer intravenously day 1 , 8 15 every 21-day cycle . The first treatment cetuximab large dose . Beginning second treatment , participant receive small dose cetuximab . - Blood work repeat every clinic visit day 1 8 . During cycle 1 , blood also draw day 15 . - Tumor assessment repeat 6 week , 12 week , every 9 week thereafter , assess CT scan abdomen , pelvis , chest x-ray . MUGA scan repeat every 4 cycle ( 12 week ) . - Participants may continue receive cycle study treatment long disease progress experience serious side effect .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic proof adenocarcinoma colon rectum evidence metastatic disease . The site primary lesion must confirm endoscopically , radiologically , surgically large bowel Patients must receive one ( one ) prior chemotherapy regimen metastatic disease use 5FU/LV Xeloda combination oxaliplatin Avastin . &gt; 4 week must elapse time major surgery &gt; 2 week must elapse time minor surgery &gt; 4 week must elapse time major radiotherapy Normal organ marrow function Measurable disease RECIST criterion Older 18 year age ECOG performance status 01 Life expectancy &gt; 12 week Previous treatment irinotecan , cetuximab SU011248 Any follow within 12 month prior study drug administration : severe/unstable angina ; myocardial infarction ; symptomatic congestive heart failure ; cerebrovascular accident ; transient ischemic attack . Known brain metastasis carcinomatous meningitis Uncontrolled serious medical psychiatric illness NCI CTCAE grade 3 great hemorrhage within 4 week start study treatment Uncontrolled hypertension Diagnosis secondary malignancy last 5 year , except adequately treat basal cell carcinoma , squamous cell skin cancer , localize prostate cancer normal PSA within past 3 month , situ bladder cancer , situ cervical cancer Pregnant breastfeed Concurrent treatment another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sutent</keyword>
</DOC>